5th consecutive win! Medicilon once again made the list of "Top 20 Chinese R&D CRO Enterprises in 2024"

On July 4^th, the 2024 International Pharmaceutical Services Industry Innovation and Development Conference, along with the 9^th Summit for China Pharmaceutical R&D Innovation, was grandly held at the Xiongan Convention and Exhibition Center. At the conference, the highly anticipated "2024 China Pharmaceutical R&D Strength Ranking" was announced. Shanghai Medicilon Inc. (Medicilon) stood out among hundreds of pharmaceutical enterprises and was honored with the "Top 20 Chinese R&D CRO Enterprises in 2024" award.

top 20 cro.webp

About the Top 20 Chinese R&D CRO Enterprises in 2024

The "2024 China Pharmaceutical R&D Strength Ranking" is selected by the Organizing Committee of the China Pharmaceutical R&D Innovation Summit and the Expert Committee of the 2024 China Pharmaceutical R&D Strength Ranking. It aims to uncover and drive innovative forces in pharmaceutical R&D, encourage and recognize enterprises making significant contributions to pharmaceutical R&D, and further enhance the industry's focus on innovation in pharmaceutical R&D. The "Top 20 Chinese R&D CRO Enterprises in 2024" list is strictly evaluated based on ten criteria such as annual total revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, personnel size, personnel size growth, brand recognition, and leadership in specific subfields. These criteria represent the highest standards in the Chinese pharmaceutical CRO industry.

此博客中的热门博文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Pharmacokinetics Services

Pharmacokinetics Services Our pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai government. Preclinical Pharmacokinetics Method development and validation (GLP,Non-GLP) Bioanalysis Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies, Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB penetration ) Stability in vehicles and plasma Drug interaction studies In vitro metabolic stability CYP 450 inhibition Plasma protein binding studies Distribution studies Excretion studies Prediction an...

阅读全文

Shanghai Medicilon Inc.

搜索此博客